Davis Polk advised J.P. Morgan Securities LLC as the sole book-running manager and representative of the underwriters on a registered public offering by Savient Pharmaceuticals, Inc. of $230 million aggregate principal amount of its 4.75% convertible senior notes due 2018 (which included the full exercise of the over-allotment option). 

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase), which was approved by the FDA on September 14, 2010, for the treatment of chronic gout in adult patients refractory to conventional therapy. 

The Davis Polk corporate team included partner Richard D. Truesdell Jr., associate Jason Roomer and foreign temporary associate Siphile Buthelezi (admitted only in South Africa). Partner John M. Brandow and associates Jenny M. Dahlen and Jay A. Osha provided equity derivatives advice. Partner Michael Farber and associate Brian Radigan provided tax advice. Associate Randy Samson provided intellectual property advice. Joshua Sills was the legal assistant for the transaction. All members of the Davis Polk team are based in the New York office.